PLx Pharma (PLXP) Receives Average Recommendation of “Hold” from Analysts

PLx Pharma (NASDAQ:PLXP) has received an average recommendation of “Hold” from the five analysts that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $13.00.

Separately, Janney Montgomery Scott began coverage on PLx Pharma in a research note on Friday, January 19th. They issued a “buy” rating and a $14.00 price target for the company.

How to Become a New Pot Stock Millionaire

NASDAQ:PLXP traded up $0.05 on Wednesday, hitting $3.50. 10,198 shares of the stock were exchanged, compared to its average volume of 15,128. PLx Pharma has a 52 week low of $3.20 and a 52 week high of $11.20. The company has a debt-to-equity ratio of 1.51, a current ratio of 14.19 and a quick ratio of 14.06.

PLx Pharma (NASDAQ:PLXP) last announced its quarterly earnings data on Friday, March 23rd. The biotechnology company reported ($0.48) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.07. The firm had revenue of $0.34 million for the quarter. equities research analysts anticipate that PLx Pharma will post -1.63 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC boosted its holdings in shares of PLx Pharma by 44.4% in the 4th quarter. Renaissance Technologies LLC now owns 32,512 shares of the biotechnology company’s stock valued at $224,000 after buying an additional 10,000 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in shares of PLx Pharma by 120.0% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 550,000 shares of the biotechnology company’s stock valued at $361,000 after buying an additional 300,000 shares during the last quarter. Finally, Brown Advisory Inc. acquired a new stake in shares of PLx Pharma in the 4th quarter valued at approximately $759,000. 25.01% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “PLx Pharma (PLXP) Receives Average Recommendation of “Hold” from Analysts” was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://weekherald.com/2018/04/24/plx-pharma-plxp-receives-average-recommendation-of-hold-from-analysts.html.

PLx Pharma Company Profile

PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing nonsteroidal anti-inflammatory drugs and other pharmaceutical agents. Its lead product is Aspertec 325 mg, a novel formulation of aspirin that uses the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply